Table 2 Treatment and outcome of reported cases of patients with GIST after organ transplantation
Case | Author | Size (cm) | Nuclear mitotic counts | Fletcher’s criteria | Joensuu’s criteria | Introduction of Imatinib | Immunosuppression before the treatment | Immunosuppression after the treatment | Outcome/Months |
|---|---|---|---|---|---|---|---|---|---|
1 | Agaimy | 3.5 | < 5/50 HPF | Low | Low | Not described | Not described | Not described | Alive/68 |
2 | Agaimy | 23.0 | 14/50 HPF | High | High | Not described | Not described | Not described | Not described |
3 | Saidi | 2.5 | < 5/50 HPF | Low | Low | None | Tac, Azathioprine | Not described | Alive/18 |
4 | Camargo | 5.0 | 5/50 HPF | Intermediate | Low | None | Tac | Not described | Alive/20 |
5 | Tu | 4.5 | 2–3/50 HPF | Low | Low | None | CsA, MMF, Steroid | Steroid withdrawn CsA and MMF were reduced at half dosage | Alive/24 |
6 | Mulder | 5.0 | > 10/50 HPF | High | High | 400 mg/day → 200 mg/day | CsA, Steroid | CsA dosage was reduced from 110 mg daily to 75 mg daily | Recurrence/21 Death/44 |
7 | Mrzljak | 1.0 | 1/50 HPF | Low | Low | None | Tac, MMF | Not described | Death/38 Unknown cause |
8 | Cimen | 15.0 | 14/50 HPF | High | High | 400 mg/day | CsA, Azathioprine, Steroid | CsA trough level at 200–350 μg/L | Alive/12 |
9 | Cheung | 3.0 | 9/50 HPF | High | Intermediate | None | CsA → Tac Azathioprine →MMF, Steroid | Tac trough level at 2.6 μg/L MMF was replaced with Everolimus (trough level at 6.7 μg/L) | Liver metastasis/24 Death/24 Multidrug-resistant bacterial pneumonia |
10 | Cheung | Not described | Not described | Not described | Not described | 400 mg/day | CsA, MMF | CsA withdrawn Sirolimus introduction (trough level at 5.1 μg/L) | Alive/120 |
11 | This case | 11.0 | 20/50 HPF | High | High | 400 mg/day → 300 mg/day | CsA, MMF, Steroid | CsA withdrawn | Alive/18 |